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Accommodating Complex Aortic Neck Morphology
During EVAR: A Prospective Analysis of Stentgrafts
With Suprarenal Fixation
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Objectives: The use of Palmaz stent for type I en-
doleaks during endovascular aneurysm repair (EVAR) in
patients with complex aortic neck (AN) morphology is
associated with increased morbidity. This study evaluates
the use of Palmaz stents during EVAR using stentgrafts
(SG) with supra-renal fixation in patients with complex AN
morphology.
Methods:Two hundred consecutive patients undergo-
ing EVAR using SG with suprarenal fixation (Talent: n 
100, and Zenith: n 100) were evaluated. During EVAR,
persistent type I endoleaks were treated by placement of a
Palmaz stent. All CTA images were analyzed for AN mor-
phology including neck length, diameter, angulations, and
thrombus. Data was prospectively entered into a vascular
registry and analysis included medical risk factors, AN
morphology, the need for Palmaz stent for type I en-
doleaks, and postoperative morbidity and mortality.
Results: Of the 200 EVAR, patients with the Talent
(n  100) and the Zenith (n  100) SG had comparable
demographics, and AAA size. The AN morphology was
also comparable between the Talent (T) and the Zenith (Z)
groups with respect to median AN length (T: 12.5mm,
Z:12.0mm), AN diameter (T: 27mm, Z: 29mm), AN
angulations (T: 12%60°, Z: 6%60°), and AN thrombus
3mm (T:18%, Z: 13%). Patients with the Talent stent-
graft had a significantly lower incidence of type I endoleaks
requiring Palmaz stents (9% vs 26%, p  0.05). Postopera-
tively, the incidence of type I (T: 3%, Z: 4%) and type II (T:
29% vs Z: 23%) endoleaks were similar between the groups.
Conversion to open repair was required in (3) 3% of Zenith
SG patients and none of the Talent SG patients. The 30-day
mortality in both groups was 0%.
Conclusions: AAA with complex and short AN length
can be treated successfully using the Talent and the Zenith
SG. However, in patients with comparable AN morphol-
ogy the incidence of type I endoleaks requiring Palmaz
stents is significantly greater when using the Zenith SG.
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Objectives: Anastomotic pseudoaneurysms and true
paraanastomotic aneurysms (PAA) after initial abdominal
aortic prosthetic reconstruction often need reintervention,
since they are at risk for rupture. However, open surgical
reinterventions are technically challenging procedures with
highmortality andmorbidity rates. In the present study, we
describe the long-term clinical course in a large series of
patients with endovascular repair of PAAs.
Methods: A retrospective analysis of a prospective da-
tabase was performed. All patients treated with an endovas-
cular stentgraft between July 1999 and July 2009 for an
aorto-iliac PAA after previous aortic prosthetic reconstruc-
tion in one of the four participating centers, were included
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reinterventions, and length of hospital stay.
Results: Fifty-eight patients (mean age 71 years (range
49-87), 53 (91%) males) with a total of 80 aortic and/or
iliac pseudo or true PAA were treated with an endovascular
stentgraft. Devices that were used were tube grafts (n 8),
bifurcated stentgrafts (n  32), aorto-uni-iliac stentgrafts
(n  7), and iliac extension grafts (n  11). Technical
success rate was 95%. Median hospital stay was 3 days
(range 1-122). The 30-day mortality rate was 3.4% (n 2).
Mean follow-up was 41 months (range 0-106). Procedure
related and cumulative mortality rate was 10% (n  6) and
19% (n  11), respectively. CTA revealed 9 endoleaks (3
type I and 6 type II) in 8 patients and endotension in 2
patients. Type I endoleaks were observed in 25% of patients
treated with endovascular tube grafts. The overall reinter-
vention rate was 19% (n 11) with an annual risk of 4.7%.
In non-tube graft patients the annual risk was 4.0%.
Conclusions: The present study shows that endovas-
cular repair with bifurcated or aorto-uni-iliac stentgrafts of
paraanastomotic aortic and iliac aneurysms after initial
prosthetic aortic surgery is a durable alternative to open
reconstruction.
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Objectives: AAA growth following endovascular aneu-
rysm repair (EVAR) in patients with type 2 endoleaks is
associated with adverse outcomes. We sought to evaluate
the success of embolization of type 2 endoleaks in prevent-
ing AAA sac growth.
Methods: We conducted a retrospective review of pa-
tients (pts) who underwent EVAR and were treated for a
type 2 endoleak. CT scans were evaluated for AAA size
from time of endoleak treatment. The embolization mate-
rial, graft, target, and co-morbidities were evaluated for
their association with change in sac size.
Results: Since 2000, 95 patients underwent 140 em-
bolizations to treat a type 2 endoleak. The median age was
77 (73, 83), 87% were men and 13% women. The mean
time from EVAR to embolization was 26.1/-22.2
months; the average increase in size of the AAA sac from
EVAR to treatment was 0.7x0.5 cm. The average number
of embolizations/patient post EVAR was 1.6  0.8. Thedistribution of vessels embolized at first and subsequent set-
tings were: ima- 37%/38%; lumbar- 38%/38%; proximal hy-
pogastric 11%/9%; AAA sac- 11%/14%; other 3%/2%. 13
patients underwent simultaneous embolization of two targets.
61% of patients were embolized with glue, 29% coils, 7% glue
& coils, and 3% gelfoam. 8 pts (8.4%) underwent graft ex-
plant. 19 (20%) of pts required two or more embolization
procedures. There was no difference between target vessel
treated or treatment modality in halting sac expansion (
5mm). No pt ruptured their AAA. One year cumulative
survival was 92% (87, 97.8), freedom from sac expansion (
5mm) 81.5% (72.6, 90.4), and freedom from second embo-
lization procedure 84.9 % (77.3, 92.5). Mutivariable analysis
identified continued tobaccouse to predict sac expansion (5
mm) 2.05 (0.88, 4.77; p 0.09).
Conclusions:Embolization of type 2 endoleaks prevents
AAA rupture and reduces AAA growth in the majority of pts
who have AAA growth and a type 2 endoleak following
EVAR.However, continued close surveillance is warranted in
a minority of patients who have continued sac growth.
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Objectives: To examine the fate of aneurysmal iliac
arteries managed during EVAR for AAA.
Methods: We analyzed data from the Cook Zenith
trial. Follow up was at 1, 6, 12 months, and annually for 5
years. Patients were evaluated according to the largest iliac
artery diameter: Group A (20mm) and Group B (
20mm). These groups were further subdivided based on
iliac artery growth  5mm during follow-up. The Fisher’s
exact test and chi square test were used.
Results: Of 736 patients treated, 671 had follow-up
(Group A 274). In Group A 220 (80%) were treated with
flared limbs in the common iliac artery. Group A did not
demonstrate increased iliac growth as compared to group
B. Furthermore, both groups had a similar percentage of
patients that experienced iliac artery expansion 32.1% and
31.5%. Extension to the external iliac artery did not affect
